US82640U4040 - Common Stock
Sierra Oncology Inc
NASDAQ:SRRA (6/30/2022, 7:00:01 PM)
After market: 54.99 0 (0%)54.99
+0.02 (+0.04%)
Sierra Oncology, Inc. is a clinical stage drug development company of therapeutics for the treatment of cancer. The company is headquartered in Vancouver, British Columbia and currently employs 109 full-time employees. The company went IPO on 2015-07-16. The Company’s lead product candidate, momelotinib, which is a selective and orally bioavailable janus kinase one (JAK1), janus kinase two (JAK2) and activin a receptor type one (ACVR1) inhibitor under investigation for the treatment of myelofibrosis. The firm is also developing a portfolio of deoxyribonucleic acid (DNA) damage response (DDR) assets, consisting of SRA737 and SRA141. SRA737 is a bioavailable small molecule inhibitor of checkpoint kinase 1 (Chk1), which is a key regulator of cell cycle progression and the DDR network. SRA141 is a bioavailable small molecule inhibitor of Cell division cycle 7 kinase (Cdc7).
Sierra Oncology Inc
2150 ? 885 West Georgia Street, Suite 110
Vancouver BRITISH COLUMBIA V6C 3E8
P: 16045586536.0
CEO: Stephen G. Dilly
Employees: 109
Website: https://www.sierraoncology.com/
These biotech stocks face some key make-or-break events in June that could have big implication for their futures.
It could be a “never-before, never-after opportunity” to buy into these biotech stocks that trade at very attractive valuations.
Here you can normally see the latest stock twits on SRRA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: